News &

Press

venBio news

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply

Aug 12, 2021

Elevation Oncology Announces Pricing of Initial Public Offering

Jun 24, 2021

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Jun 15, 2021

Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.

Jun 8, 2021

NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial

May 26, 2021

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

May 14, 2021

Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives

May 10, 2021

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2023 venBio. All Rights Reserved.